Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer
Primary Objective:

* Response rate (by contrast CT scan)

Secondary Objectives:

* Progression-free survival (PFS)
* Overall survival (OS)
Lung Neoplasms
DRUG: DOCETAXEL|RADIATION: Intensity Modulated Radiotherapy (IMRT)|DRUG: CISPLATIN
Response rate (by contrast CT scan), 12 weeks after completion of adjuvant chemotherapy or within 4 weeks after premature study discontinuation
Progression Free survival (PFS), Day 1 of treatment to the date of objective disease progression|Overall survival (OS), Day 1 of treatment to the date of death due to any cause|Adverse events (including oesophageal and pulmonary toxicities), Informed consent signature up to 12 weeks after completion of treatment
The duration of the study for each patient will include an up to 6-week screening phase, 12 weeks treatment phase (including a resting period of 2 weeks) followed by a long-term follow-up.